AmCad BioMed Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 15.61 million compared to TWD 17.35 million a year ago. Net loss was TWD 13.01 million compared to TWD 11.48 million a year ago. Basic loss per share from continuing operations was TWD 0.24 compared to TWD 0.22 a year ago.
For the six months, sales was TWD 26.14 million compared to TWD 34.58 million a year ago. Net loss was TWD 23.6 million compared to TWD 19.21 million a year ago. Basic loss per share from continuing operations was TWD 0.44 compared to TWD 0.36 a year ago.